HawkinsPN, LavenderJP, PepysMB. Evaluation of systemic amyloidosis by scintigraphy with 123I-labeled serum amyloid P component. N Engl J Med1990; 323: 508–13.
4.
HutchinsonWL, MatherSJ, StaltieriM, Scintigraphic imaging of amyloid deposits with 99mTc-labelled serum amyloid P component. In: KisilevskyR, BensonMD, FrangioneB, GauldieJ, MuckleTJ, YoungID (eds). Amyloid and Amyloidosis 1993. Pearl River, New York: Parthenon Publishing, 1994: 682–4.
5.
KyleRA, GreippRR. Amyloidosis (AL): Clinical and laboratory features in 229 cases. Mayo Clin Proc1983; 59: 665–83.
6.
GertzMA, KyleRA, GreippPR. Response rates and survival in primary systemic amyloidosis. Blood1991; 77: 257–62.
7.
BrownMP, WallsRS. Amyloidosis of immunoglobin origin: Useful treatment. Med J Aust1990; 152: 95–100.
8.
SolomonA, WeissDT. Ominous consequences of immunoglobulin deposition. N Engl J Med1993; 329: 1422–3.
9.
van BurenM, HenéRS, VerdonckLF, VerzigbergenFJ, LokhorstH.Clinical remission after syngenic bone marrow transplantation in a patient with AL amyloidosis. Ann Intern Med1995; 122: 508–10.
10.
MarietteX, ClauvelJP, BrouetJC. Intensive therapy in AL amyloidosis and light-chain deposition disease. Ann Intern Med1995; 123: 553.
11.
ScheinbergMA, CathcatES. Comprehensive study of humoral and cellular immune abnormalities in 26 patients with systemic amyloidosis. Arthritis Rheum1976; 19: 173–8.
12.
WolfBC, KumarA, VeraJC, NeimanRS. Bone marrow morphology and immunology in systemic amyloidosis. Am J Clin Pathol1986; 86:84–8.
13.
DurieBGM, SalmonSE. A clinical staging system for multiple myeloma. Cancer1975; 36: 842–54.
14.
GreippPR, LustJA, O'FallonWM, Plasma cell labelling index and ß-2 microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood1993; 81: 3382–7.
